Healthcare Expenditure
Adult vaccination programmes deliver socio-economic benefits up to 19 times initial investment, according to new report
18 April 2024
Our new report examines the promise of prevention in healthcare and provides six key recommendations that could usher in a new era of optimised prevention.
Grow and diversify funding for prevention to boost the nation’s health and prosperity, urges landmark report
12 October 2023
Our new report examines the promise of prevention in healthcare and provides six key recommendations that could usher in a new era of optimised prevention.
G7 Investments in New Antibiotics Would Pay Off – For Everyone
9 December 2022
Programs to incentivise antibiotic R&D are underway in the UK and under consideration in the US, EU, Canada, and Japan. We have assessed the benefits and costs to the members of the G7/EU and project that all G7/EU members would see big payoffs ranging from 11:1 in the UK to 28:1 for the US and Japan. Global returns from reducing the 1.27m people dying each year from AMR are even higher.
OHE Critique of CBO’S Pharmaceutical Investment Model Provides Warning for Policymakers on Reliability of Estimates
3 December 2021
As US policymakers consider the potential implications of the drug pricing reforms contained within the Build Back Better Act, OHE releases a critique of the Congressional Budget Office scoring, demonstrating that the estimates are highly uncertain and policymakers should exercise caution when relying upon them.
Does the New CBO Report Change Anything?
15 September 2021
Since we began our project to consult experts on the impact of H.R. 3. on pharmaceutical innovation the CBO has released a new working paper. Given…
Due to the Unprecedented Nature of H.R. 3, the CBO Analysis is Unreliable and Can’t Inform Policymaking
15 September 2021
As we have discussed in the previous blogs in our Series on H.R. 3, the Congressional Budget Office (CBO) have attempted to estimate the potential effect…
CBO Doesn’t Capture The Real Impact of H.R. 3 on Innovation
14 September 2021
In our previous blog we discussed how analyses of the impact of H.R. 3 published by the Congressional Budget Office (CBO) do not reflect the process…
The CBO Doesn’t Understand Investors
13 September 2021
Our second blog in the OHE H.R. 3 Series discusses how the Congressional Budget Office (CBO)’s analysis of H.R.3 does not reflect the reality of biopharmaceutical…
H.R. 3 is the Wrong Policy for the Wrong Problem
10 September 2021
US policy makers are discussing an attempt to lower prescription drug spending in the US. US policy makers are currently discussing the Elijah E. Cummings Lower…